Author

Sandra Erntoft

Observed names: Erntoft, Sandra, S. Erntoft, Sandra T. Erntoft, Sandra T. Erntoft Idemyr

Institution: Leo Pharma (Denmark)

Observed institutions: Lund University, Leo Pharma (Denmark)

OpenAlex ID: A5006344351

A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values

2015 · Nina Karaoghlanian, Sandra Erntoft, et al. · Patient Related Outcome Measures · 112

A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis

2015 · Eggert Stockfleth, Ketty Peris, et al. · International Journal of Dermatology · 40

Ingenol mebutate gel for actinic keratosis: The link between quality of life, treatment satisfaction, and clinical outcomes

2015 · Matthias Augustin, John H. Tu, et al. · Journal of the American Academy of Dermatology · 36

Pharmaceutical Priority Setting and the Use of Health Economic Evaluations: A Systematic Literature Review

2011 · Sandra Erntoft · Value in Health · 32

Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States

2016 · Steven R. Feldman, Anders Holmen Moeller, et al. · Journal of health economics and outcomes research · 30

Physician perceptions and experience of current treatment in actinic keratosis

2014 · E. Stockfleth, K. Peris, et al. · Journal of the European Academy of Dermatology and Venereology · 30

Patient-reported adherence and persistence to topical treatments for actinic keratosis: a longitudinal diary study

2016 · S. Erntoft, J.M. Norlin, et al. · British Journal of Dermatology · 11

Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States

2016 · Carl V. Asche, Panagiotis Zografos, et al. · Value in Health · 10

The use of health economic evaluations in pharmaceutical priority setting - The case of Sweden

2010 · Sandra Erntoft · Lund University Publications (Lund University) · 10

Patient Adherence And Non-Persistence Behaviour In Real Life Actinic Keratosis (Ak) Topical Treatment In The Uk, Germany And France

2014 · S. Erntoft, J. Norlin, et al. · Value in Health · 4

Quality Of Life In Patients Suffering From Psoriasis Vulgaris Using Eq5d; A Systematic Literature Review

2014 · A. Moeller, S. Erntoft, et al. · Value in Health · 2

The use (or rather the non-use) of cost-effectiveness data in priority setting decisions – are we underestimating the barriers to using health economics in real world priority setting decisions? Comment on "Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden"

2015 · Sandra T. Erntoft · International Journal of Health Policy and Management · 1

PSS25 Actinic Keratosis Patients are Willing to Pay for Shorter Treatment and Local Skin Response Duration and Ingenol Mebutate Gel is Likely to Increase Patient Likelihood of Successful Completion of Topical Treatment

2012 · M. Willis, S. Erntoft, et al. · Value in Health · 1

Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting

2014 · Michael Willis, Sandra Erntoft, et al. · Journal of health economics and outcomes research

Vilken betysdelse har hälsoekonomi vid prioriteringar? Ett experiment bland beslutsfattare och en analys av faktiska prioriteringar.

2010 · Sandra Erntoft, C Asserburg, et al. · Lund University Publications (Lund University)

Works count: 16

Citation count: 319

H-index: 9

I10-index: 9